# China NMPA Drug Inspection - Yunnan Suimin Biotechnology Development Co., Ltd. - Epimedium

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/yunnan-suimin-biotechnology-development-co-ltd/f611734f-e841-4307-b8f0-16d2716decd7/
Source feed: China

> China NMPA drug inspection for Yunnan Suimin Biotechnology Development Co., Ltd. published April 23, 2020. Drug: Epimedium. The Yunnan Provincial Drug Administration released its 2020 Issue 1 announcement on April 23, 2020, identifying several 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Yunnan Provincial Drug Administration's First Announcement of Substandard Drug Quality in 2020
- Company Name: Yunnan Suimin Biotechnology Development Co., Ltd.
- Publication Date: 2020-04-23
- Drug Name: Epimedium
- Inspection Finding: The following items do not meet the requirements: [Inspection] Total ash content, [Content determination]
- Summary: The Yunnan Provincial Drug Administration released its 2020 Issue 1 announcement on April 23, 2020, identifying several substandard drug products discovered during provincial quality inspections. This regulatory action involved multiple manufacturers and suppliers, including Yunnan Suimin Biotechnology Development Co., Ltd., Yibin Renhe Traditional Chinese Medicine Pieces Co., Ltd., and Anhui Jiuzhou Jinnuo Pharmaceutical Co., Ltd. The inspections, primarily targeting traditional Chinese medicine components such as Chrysanthemum, Epimedium, and Myrrh, were conducted based on the standards set by the 2015 edition of the Chinese Pharmacopoeia. Major violations identified included failures in physical properties, incorrect processing methods, and substandard chemical content. Specifically, several batches failed safety tests for sulfur dioxide residue and excessive ash content. Notably, the report highlighted instances where drugs were not produced by the indicated manufacturers, suggesting supply chain irregularities or mislabeling. These findings were confirmed by regional testing institutes, including the Kunming Municipal Institute of Food and Drug Control. In response, the regulatory framework requires the public disclosure of these failures to ensure medication safety. Required actions involve the removal of non-compliant products from the market and increased supervision of the involved entities to prevent the distribution of substandard batches to healthcare facilities and pharmacies.

Company: https://www.globalkeysolutions.net/companies/yunnan-suimin-biotechnology-development-co-ltd/db90dc7b-b4ab-4d81-a74c-36cf7799aaa4/